AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 231 min read$CSTL

MAETZOLD DEREK J sold $303K of CSTL

MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 8,580 shares of CASTLE BIOSCIENCES INC (CSTL) at $35.33 ($0.30M total) on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAETZOLD DEREK J
Published Sep 23, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Neutral
medium confidence
Mentioned
$CSTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑planned, suggesting limited immediate price impact.

02

Market read

Provides investors with the latest insider activity for CSTL, useful for compliance and monitoring but low trading relevance.

03

What to watch

The sale was pre‑arranged under a 10b5‑1 plan, reducing the likelihood of new negative information.

Relevance 3/10Novelty 4/10Timing: post‑market filing on Sep 23, 2026

Background

Form 4 filings disclose insider transactions and are required by the SEC for transparency.

Company-level read

Ticker impact

$CSTLNeutralMedium confidence
Context

CEO Derek Maetzold sold 8,580 shares for $303,166 via a 10b5‑1 plan, reducing his stake to 21,479 shares.

Expected impact

Potential short‑term pressure on CSTL stock, likely limited to a few basis points.

Evidence & confidence

The transaction is a routine 10b5‑1 sale of modest size; markets typically view such sales as low‑impact unless unusually large.

Market effects

Sector

No broader sector impact; insider activity is company‑specific.

Regional

Limited to U.S. biotech investors.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

Some traders may view any insider sell as a bearish signal and short the stock.

Key entities

  • Executive
    Derek J. Maetzold

    President & Chief Executive Officer of Castle Biosciences

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

SEP 28
$CSTLMedAI 8/10

Castle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.

rttnews.com2 min
AUG 8
$CSTLMedAI 8/10

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.

fool.com6 min
JUL 30
$CSTLHigh

CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to

SEC EDGAR 8-K6 min